Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Shareholder Meeting (November 2021)
16 slides from Argenica Therapeutics's shareholder meeting presentation, Nov 16, 2021
Slide 1: Argenica Therapeutics Annual General Meeting
ARGENICA THERAPEUTICS ANNUAL GENERAL MEETING 16 NOVEMBER 2021 1 www.argenica.com.au
Slide 2: Disclaimer
This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You shoul
Slide 3: Granted Patents
ARGENICA THERAPEUTICS GRANTED PATENTS Granted in the EU, Japan Commercialise “best in class” Neuroprotective peptide and China, and a US national novel neuroprotective that is progressing to Phase 1 filing in progress. therapeutics to reduce brain clinical trials in healthy cell death following stro
Slide 4: Capital Structure and Share Price
$0.60 Total Shares on issue 73,172,250 $0.50 ARGENICA THERAPEUTICS Shares subject to escrow for 12 months 1 3,322,500 $0.40 Shares subject to escrow for 24 months 2 22,625,752 4.7% 5.4% 3.7 19% 21% 47% $0.30 Options on issue (escrow for 24 months) 2 & 3 8,300,000 Options on issue 4 800,000 $0.20 Cas
Slide 5: Recent milestones and progress
Highly encouraging results from A$290,000 grant secured to pilot pre-clinical pharmacokinetics Argencia partners with advance pre-clinical research of study Linear for Phase 1 clinical ARG-007 in preparation for Phase trial, initiates trial pre- NO ADVERSE EFFECTS 1 trials activities ARGENICA THERAP
Slide 6: Potential benefits of ARG-007
Simple injection for paramedics to Extends the treatment window for use in emergency stroke scenarios stroke patients who have to travel significant distance for treatment ARGENICA THERAPEUTICS Protects the brain against the Reduces special care requirements and damaging effects of stroke intensive
Slide 7: Pre-clinical results for ARG-007
REDUCES BRAIN POTENTIAL TO SAFE WITH NO TISSUE DEATH ADMINISTER IN ADVERSE EFFECTS THE FIELD ARGENICA THERAPEUTICS Pre-clinical studies showed ARG-007 No adverse effects were ARG-007 showed a 67% does not exacerbate bleeding in observed in a PK animal study, reduction in brain tissue hemorrhagic str
Slide 8: Development timeline
Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2021 2021 2022 2022 2022 2022 Contra-indication Assessment ARGENICA THERAPEUTICS GMP Manufacturing Formulation & Stability Pharmacokinetics Safety & Toxicology Phase 1 Clinical Trial Funded pre-IPO raise To be funded from IPO Key progress milestones 8 Indicative schedule on
Slide 9: Pre-clinical and Phase 1 study activities
ARGENICA THERAPEUTICS Completion of preliminary study activities, including clinical site management setup, preparation of ethics submission and healthy volunteer patient recruitment. ANIMAL STUDY ANIMAL STUDY IN-HUMAN STUDY Determines how is Characterise the safety profile of absorbed, distributed,
Slide 10: Phase 1 clinical trial design
ARGENICA THERAPEUTICS 4 cohorts, with each cohort Single site study conducted at Estimated 6 months, with Double-blind, randomised receiving a different dose of the Linear Clinical Research preliminary findings expected study where participants either 8 participants in facility in Western Australia.
Slide 11: Phase 1 trial objectives
1. IMPROVE THE OF HOW EFFECTS THE BODY ARGENICA THERAPEUTICS 2. EVALUATE THE WHEN ADMINISTERED 3. DETERMINE THE 11 4. IDENTIFY ANY POSSIBLE www.argenica.com.au
Slide 12: Beyond Phase 1: other brain injury indications
Data collected from the Phase 1 clinical trial will be critical to progress into Phase 2 trials, where will be administered to stroke patients. While stroke is the current corporate and commercial focus, ARGENICA THERAPEUTICS safety data from the Phase 1 clinical trial can potentially be used to mov
Slide 13: Board and management
Geoff Pocock Dr Liz Dallimore Non-Executive Chairman CEO • 20 years’ experience in commercialisation of emerging • Over 20 years' experience in R&D, technology technologies and capital markets commercialisation and management consulting, including • Non-Executive Director of EMVision Medical Devices
Slide 14: Scientific and clinical advisors
Prof. Bruno Meloni Geoffrey Donnan CSO & Research Lead Member - CAC Head of Stroke Laboratory Research at UWA and the Perron Institute. Professor Professor of Neurology at The University of Melbourne and former Director Meloni has over 25 years experience as a research scientist, the last 20 in the
Slide 15: Investment highlights
3# PRE-CLINICAL DATA Positive pre-clinical results provide encouraging dataset leading into in-human trials. ARGENICA THERAPEUTICS 1# CLEAR PATHWAY TO TRIALS 2# 4# 5# Clear clinical pathway and EXCEPTIONAL NEAR TERM robust capital position to UNMET CLINICAL NEED TEAM CATALYSIS execute Phase 1 clinic
Slide 16: For further information please contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO E: info@argenica.com.au 16 www.argenica.com.au
Argenica Therapeutics — Shareholder Meeting (November 2021) on 6ix